ArticleScientific reports2025
Identification and experimental validation of autophagy-related genes in focal segmental glomerulosclerosis by integrating bioinformatics and machine learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Focal segmental glomerulosclerosis (FSGS) is a common chronic glomerular disease characterized by podocyte injury. The aim of the present study was to investigate autophagy-related characteristics in FSGS. GSE200828, GSE99340, GSE47183, GSE108109, and GSE104948 were used as training sets, and GSE129973 was used as the validation set. 222 autophagy-related genes (ARGs) were incorporated. Autophagy-related differentially expressed genes (ARDEGs) were obtained and then analyzed using violin plots, PPI network analysis, functional enrichment analysis, gene set enrichment analysis, immune cell infiltration and cMAP. Two machine learning methods were applied to select candidate ARGs. Nomogram and receiving operating curve were conducted to assess diagnostic value and screen out core genes. An in vivo rat model of FSGS was established to verify expression of core genes via WB and qRT-PCR. The results indicated that nine ARDEGs were identified. PPI network contained nine nodes and 30 edges, and TP53 had the highest degree value. ARDEGs were significantly enriched in physiological processes and pathways related to autophagy and immunity. Patients with FSGS had higher levels of resting natural killer cells, monocytes and activated dendritic cells, and lower levels of plasma cells, follicular helper T cells, resting dendritic cells and resting mast cells. Through cMAP analysis, 10 small molecule compounds were identified which might work as potential therapeutic drugs in FSGS. Next, three candidate ARGs were obtained which were further evaluated by nomogram and diagnostic value. Among them, TP53 and RELA had high diagnostic values. In vivo, TP53 and RELA were at higher levels in FSGS than in the control group. In conclusion, TP53 and RELA are promising autophagy-related diagnostic and therapeutic markers in FSGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.